| Trial ID: | L0708 |
| Source ID: | IRCT20191009045043N1
|
| Associated Drug: |
Sumac
|
| Title: |
Investigation the effect of the Sumac powder on Liver Enzymes, lipid profile, glycemic indexes, Antioxidant marker, inflammatory marker, anthropometric measurements in non-alcoholic fatty liver patients with overweight or obes
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic Fatty Liver Disease. <br>Liver disorders in diseases classified elsewhere
|
| Interventions: |
Intervention 1: Intervention group: Sumac powder capsule + diet. Intervention 2: Control group: Medicinal starch capsule + diet.
|
| Outcome Measures: |
Alanine aminotransferase (ALT) enzyme. Timepoint: Baseline and the end of the intervention. Method of measurement: ALT kit.;Aspartate aminotransferase (AST) enzyme. Timepoint: Baseline and the end of the intervention. Method of measurement: AST kit.;Weight. Timepoint: Baseline and the end of the intervention. Method of measurement: scale/ kg.;Cholestrol. Timepoint: Baseline and the end of the intervention. Method of measurement: Cholestrol Kit.;Triglyceride. Timepoint: Baseline and the end of the intervention. Method of measurement: Triglyceride Kit.;Low-density lipoprotein. Timepoint: Baseline and the end of the intervention. Method of measurement: Low-density lipoprotein Kit.;High-density lipoprotein. Timepoint: Baseline and the end of the intervention. Method of measurement: High-density lipoprotein Kit.;Fasting blood suger. Timepoint: Baseline and the end of the intervention. Method of measurement: Fasting blood suger Kit.;Insulin. Timepoint: Baseline and the end of the intervention. Method of measurement: Insulin Kit.;Total Antioxidant Capacity. Timepoint: Baseline and the end of the intervention. Method of measurement: Total Antioxidant Capacity Kit.;Tumor Necrosis Factor alpha. Timepoint: Baseline and the end of the intervention. Method of measurement: Tumor Necrosis Factor alpha Kit.;Alkaline Phosphatase. Timepoint: Baseline and the end of the intervention. Method of measurement: Alkaline Phosphatase kit.;Height. Timepoint: Baseline and the end of the intervention. Method of measurement: Meter.;Waist circumference. Timepoint: Baseline and the end of the intervention. Method of measurement: Meter.;Hip circumference. Timepoint: Baseline and the end of the intervention. Method of measurement: Meter.;Fat mass. Timepoint: Baseline and the end of the intervention. Method of measurement: BIA device.;Fat Free mass. Timepoint: Baseline and the end of the intervention. Method of measurement: BIA device.;Total Body Water. Timepoint: Baseline and the end of the intervention. Method of measurement: BIA device.;Body cell mass. Timepoint: Baseline and the end of the intervention. Method of measurement: BIA device.;Gama glutamil transferase enzyme. Timepoint: Baseline and the end of the intervention. Method of measurement: gama glutamil transferase KIt.nan
|
| Sponsor/Collaborators: |
Shiraz University of Medical Sciences
|
| Gender: |
All
|
| Age: |
20 years60 years
|
| Phases: |
Phase 2/Phase 3
|
| Enrollment: |
46
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Based on block randomization and 4 blocks, the entry of patients into the two study groups will be randomized by using
|
| Start Date: |
20/01/2020
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
24 February 2020
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/43090
|
